culture filtrate using ion-exchange or by solvent extraction. The antibiotic was obtained as a crystalline substance with ultraviolet absorption maximaat 230 and 310 nm, [a]D+525°(in dimethylformamide); the empirical formula-C24H31N3O7. In 1 N hydrochloric acid, sibiromycin is transformed into "the product of acidic inactivation" tabulated in Table 1 . Interaction of sibiromycin with gaseous SO2in chloroform affords the crystalline derivative, CaJH^NgCVSOa, possessing biological activity similar to that of sibiromycin. The sulfur-containing derivative of the antibiotic is crystallized from methanol and shows a UVspectrum practically identical with the spectrum of the parent sibiro- The pure methyl sibirosaminide base was converted into the hydrochloride and crystallized from anhydrous iso-propanol. On the basis of the elemental and functional analysis a molecular formula of methyl sibirosaminide hydrochloride was calculated to be C9H19NO4-HC1, M?0o-50°(c 2.0, H2O), m.p. 120~122°C (Table 2 ). Methyl sibirosaminide is not hydrolyzed with In aqueous HG1 (3 hours, 100°C) and gives neither ammonia nor other volatile amines on treatment with hot alkali. Acetylation of the methyl glycoside with Ac2O in pyridine yields the diacetate C13H23NO6, Md0'-70°(c 0.4, methanol), m.p. 135~136°C. In the infrared spectrum of the diacetate there is absorption at 3450cm"1 (OH). Additional acetylation of the diacetate with Ac2O in triethylamine with 4-dimethylamino-pyridine4) yielded the triacetate, C15H25NO7, Mjf-250 (c 0.3, methanol), m.p. 127~128°C. Hydrolysis of PAI with 6n aqueous hydrochloric acid (45min., 100°C) affords a bright yellow crystalline substance named "the product of acidic hydrolysis" (PAH) C16HUN2O3. PAH is soluble in pyridine, sparingly soluble in ether and acetone, slightly soluble in alcohol and insoluble in benzene, chloroform and water. Catalytic reduction (Pd-C) of PAHresulted in uptake of 4 equivalents of hydrogen and afforded the colourless octahydro-PAH, C16H22N2O3, the UV-spectrum shows the same maxima, as the UV-spectrum of octahydro-PAI, at 229, 260 (shoulder) and 350nm. Infrared spectru m of PAHis shown in Fig. 4b . PAHis very stable totheacids, butiseasily hydrolized with 0.1 n aqueous NaOH(30min., 100°C) yielding colorless crystalline substance, C8H9NO' named "the product of basic hydrolysis" TBH in KBr tablet (Fig.  5) shows a strong C=O absorption band at 1670cm \ with ;2,4-dinitrophenyl hydrazine PBHaffords the brown crystalline hydrazone. All these properties suggest that in the molecule of PBHthere is carbonyl group. We have found that PBH is formed also from PAI, but among the products of basic hydrolysis of parent sibiromycin PBHwas not detected.
In the following scheme (Scheme 2) are summarized the results of studying à"chemical transformations of sibiromycin.
Sibiromycin seems to be related to anthramycin5) and dextrochrysin6) in some physicochemical properties (UV-adsorption spectrum, extremely high dextrotation in dimethylformamide), but some distinct differences were found. The most important difference is that neither anthramycin nor dextrochrysin have an amino sugar moiety in their molecules. It was concluded that sibiromycin is a new aminoglycosidic antitumor antibiotic.
Sibiromycin inhibits growth of Bacillus mycoides and Bacillus subtilis (0.3 mcg/ml), Staphylococcus aureus (1 mcg/ml), and Escherichia coli (20mcg/ml). The activity of sibiromycin is most pronounced in the treatment of mice with inoculated squamous praegastric cancer cells (strain OG-5). After two injections of sibiromycin in maximal tolerated doses the tumors disappeared completely. The development of lymphosarcoma (strain Lyo-1) was inhibited by sibiromycin in maximal tolerated dose by 90~97 %7). The LD50of sibiromycin administered in a single dose to mice intravenously, intra- 
